Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.

Lava Therapeutics, a Netherlands-based immuno-oncology therapy spinout of Amsterdam University Medical Centers (Amsterdam UMC), secured $83m yesterday in a series C round.
The round was co-led by Novo Ventures and Sanofi Ventures, investment vehicles for pharmaceutical firms Novo and Sanofi respectively.
MRL Ventures Fund, a subsidiary of pharmaceutical firm Merck & Co’s Merck Research Laboratories division, also took part in the round, which additionally included Redmile Group, Ysios Capital, BB Pureos Bioventures, Versant Ventures and Gilde Healthcare.
…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in